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Abstract
Introduction
Placental vascular development, and ultimately placental weight, is essential to healthy fetal
development. Here, we examined placental weight in a cohort of Tanzanian women in asso-
ciation with angiogenic proteins known to regulate placental vascular development and peri-
natal outcomes.
Methods
A total of n = 6579 women with recorded placental weight were included in this study. The
relative risk of adverse perinatal outcomes (Apgar score, death, asphyxia, respiratory dis-
tress, seizures, pneumonia and sepsis) was compared between placental weight in the bot-
tom and top 10th percentiles. We quantified angiogenic mediators (Ang-1, Ang-2, VEGF,
PGF and sFlt-1) in plasma samples (n = 901) collected between 12 to 27 weeks of preg-
nancy using ELISA and assessed the relative risk of placental weight in the bottom and top
10th percentiles by protein levels in quartiles.
Results
Women with Ang-2 levels in the highest quartile had an increased relative risk of placental
weight in the bottom 10th percentile (RR = 1.45 (1.10, 1.91), p = 0.01). Women with VEGF-A
(RR = 0.73 (0.56, 0.96), p = 0.05) and PGF (RR = 0.58 (0.44, 0.72), p = 0.002) in the highest
quartile had a reduced relative risk of placental weight in the bottom 10th percentile. Low pla-
cental weight (in bottom 10th percentile) was associated with an increased relative risk of
Apgar score of <7 at 1 minute (RR = 2.31 (1.70, 3.13), p = 0.001), at 5 minutes (RR = 3.53
(2.34, 5.33), p = 0.001), neonatal death (RR = 5.02 (3.61, 7.00), p = 0.001), respiratory dis-
tress (RR = 4.80(1.71, 13.45), p = 0.001), and seizures (RR = 4.18 (1.16, 15.02), p = 0.03).
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Discussion
The association between low placental weight and risk of adverse perinatal outcomes in this
cohort suggests that placental weight could serve as a useful indicator, providing additional
insight into high-risk pregnancies and identifying neonates that may require additional moni-
toring and follow-up.
Introduction
Fetal development is critically dependent on the growth, structure and function of the pla-
centa. At term the vascular network of the placenta is over 550 km in length and 15 m2 in sur-
face area [1, 2]. As the sole source of oxygen and nutrition for the fetus, disruptions in
placental growth and function can have serious implications on in utero development. Major
complications of pregnancy, including gestational diabetes mellitus, intrauterine growth
restriction, pre-eclampsia, and preterm delivery, have been linked to placental vasculature dys-
function [1, 3–7]. Placental weight at delivery is reflective of growth in the chorionic disk, pla-
cental thickness, arborisation of the chorionic villi and total surface area for nutrient exchange
with the fetus, and is therefore considered an indicator of fetal development [1, 8–10]. Disrup-
tions to placental growth can have long-term consequences on perinatal and childhood health
and have been associated with obstetric outcomes (intrauterine growth restriction and pre-
eclampsia, maternal disease), perinatal mortality and morbidity, as well as childhood growth
and development [10–16].
Recent research suggests that the pathophysiological events leading to adverse birth out-
comes (preeclampsia, intrauterine growth restriction, preterm birth and low birth weight)
occur early in pregnancy and are closely tied to vasculogenic and angiogenic processes in the
placenta, which may be reflected in the placental weight [14, 15, 17, 18]. Vasculogenesis, the de
novo formation of new vasculature, begins at the third week post-conception and continues
throughout the first trimester and into the beginning of the second trimester. Once formed, all
villi continuously undergo angiogenesis, including both transformation (branching and elon-
gation of capillaries) and maturation/re-modelling of vessels, throughout gestation [1, 19, 20].
Placental vascularization is closely regulated across pregnancy by the vascular endothelial
growth factor (VEGF) family of proteins and the angiopoietin-Tie2 axis [18, 21, 22]. In compli-
cated pregnancies disruptions in the balance of pro- and anti-angiogenic factors can alter pla-
cental vascular development and consequently the weight of the placenta.
There are limited data reported on the relationship between angiogenic proteins, placental
weight and perinatal outcomes in resource-constrained settings. The association between pla-
cental weight and clinical outcomes established in the literature suggests that this may be an
easily assessed clinical indicator of in utero growth of the fetus, mechanisms of intrauterine
growth restriction and risk of adverse perinatal outcomes. Here, we examined placental weight
in a cohort of Tanzanian women in association with angiogenic proteins measured at mid-ges-
tation and perinatal outcomes.
Methods
Study Population
The study cohort was nested within a larger prospective trial of multivitamin supplementation
in pregnancy, conducted in Dar es Salaam, Tanzania (NCT00197548, A Trial of Multivitamins
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and Adverse Pregnancy Outcomes). The results and trial design were previously reported in
detail [23]. Briefly, HIV negative women between 12 to 27 weeks gestation (based on last men-
strual period) presenting at antenatal clinics in Dar es Salaam were invited to participate. All
women, in both daily supplementation and placebo arms, were given daily doses of iron (60
mg of elemental iron) and folic acid (0.25 mg) as well as presumptive anti-malarial therapy
with sulfadoxine-pyrimethamine tablets (Fansidar, Roche) at 20 and 30 weeks gestation as
described [23]. Any participants with missing data on placental weight were excluded from the
analysis. The parent trial enrolled a total of N = 8468 women. All women with recorded pla-
cental weight (n = 6579) were included in this study. Quantification of circulating angiogenic
factors in maternal blood samples was performed in a subset of women (n = 901). Selection
criteria for samples in biomarker testing were defined based on inclusion criteria in a parallel
study examining preterm birth and small-for-gestational age outcomes, which are higher in
primigravida. We selected pre-treatment samples (all samples were collected prior to com-
mencement on study treatment regimen) from all primigravid participants with singleton live
births, known birth outcome, recorded birth weight and placental weight in this study.
Ethics Statement
This research received ethical approval from review boards at the Muhimbili University Col-
lege of Health and Allied Sciences (Dar es Salaam, Tanzania), the Harvard School of Public
Health (Boston, Massachusetts) and the University Health Network (Toronto, Canada). Signed
consent forms were obtained from all participants enrolled in the multivitamin supplementa-
tion trial to permit blood collection and protein analysis of plasma samples.
Enzyme-linked Immunosorbent Assay
All blood samples were collected (a single sample per woman) prior to assignment to treat-
ment arms (daily micronutrient supplementation or placebo). A total of 901 samples were pro-
cessed and included in this cohort. Maternal peripheral plasma samples were collected and
stored in EDTA at -80˚C prior to testing. Plasma samples were assessed for levels of Angio-
poietin-1 (Ang-1), Angiopoietin-2 (Ang-2), Vascular Endothelial Growth Factor (VEGF-A),
Soluble fms-like tyrosine kinase 1 (sFlt-1), and Placental Growth Factor (PGF) using commer-
cially available enzyme linked immunosorbent assay (ELISA) kits (Duosets, R&D Systems,
Minneapolis, MN). All sample processing and biomarker assays were performed blinded to
the patient trial arm. All proteins were selected based on previous evidence supporting a well-
established role in placental vasculogenesis and angiogenesis [1, 3, 19].
Outcomes
Study nurses weighed placentas and infants, to the nearest 10 grams, immediately following
delivery. All placentas were weighed with membranes and umbilical cord intact. No blood was
removed from the placenta prior to weighing. Neonatal death was defined as death within the
first 28 days. A study physician made clinical diagnoses of respiratory distress, asphyxia, pneu-
monia, sepsis, and seizures post-delivery.
Statistical Analysis
Statistical analysis was performed using STATA v13 (StataCorp., College Station, TX), SAS
v9.2 (SAS Institute Inc., Cary, NC), and GraphPad Prism v6 (GraphPad Software Inc., La Jolla,
CA) software. Concentrations of proteins showed deviation from normality (Shapiro-Wilks
p< 0.05), and therefore the natural log transformation was used. Correlations between
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maternal demographics and placental weight were examined using Pearson’s correlation coef-
ficient. Log binomial regression with the log link function was used to estimate relative risks
and 95% confidence intervals for the associations between proteins and extreme deciles of pla-
cental weight and between placental weight and birth outcomes. When log binomial models
failed to converge, log poisson models were used instead [24]. Baseline variables associated
with the primary outcome of interest, placental weight, at a p-value less than 0.2 were included
in the multivariate models for the association between proteins and placental weight. For the
association between proteins and placental weight these covariates included maternal age
(continuous), marital status (yes/no), literacy (literate/illiterate), baseline gestational age (<20
weeks, 20–25 weeks, >25 weeks), and trial arm (multivitamin supplementation/placebo con-
trol). We tested for the presence of linear trends by assigning each quartile the median value
and modeling this variable as a continuous variable. Multivariate models for the association
between placental weight and birth outcomes were adjusted for treatment arm (multivitamin
supplementation/placebo control), maternal age (continuous), sex of child (male, female), ges-
tational age at trial enrolment (weeks), and gestational age at delivery (weeks).
Results
Baseline characteristics of the study cohort are reported in Table 1. The study cohort consisted
of 6,637 women. A total of 464 women had a placental weight in the bottom 10th percentile
(<400 g) and a total of 560 women had a placental weight in the top 10th percentile (>600 g).
Table 1. Baseline descriptive characteristics of the study cohort (n = 6,579)
N (%) or Median [IQR]
Treatment group Multivitamin 3,317 (50.42)
Placebo 3,262 (49.58)
Parity 1 4,691 (71.68)
>1 1,888 (28.32)
Maternal age 24.52 [21.52, 28.53]
Marital status Married/cohabiting 5,527 (84.67)
Divorced/single/widowed 1,001 (15.33)
Education (years) 0–4 612 (9.34)
5–7 303 (4.63)
8–11 4,710 (71.91)
 12 925 (14.12)
Body Mass Index (kg/m2) 23.97 [21.83, 26.71]
MUACS (cm) 26 [24, 28]
Gestational age at enrolment 21.6 (19, 24)
Hemoglobin (g/dL) 10.4 [9.4, 11.2]
Anemia at enrollment 3,887 (67.64)
Malaria) at enrollment 122 (1.89)
Sex of child Female 3,166 (48.22)
Male 3,400 (51.78)
Birth weight (g) 3100 [2800, 3500]
Small for gestational age 875 (14.87)
Large for gestational age 860 (14.61)
Gestational age at delivery 39.7 [38, 41]
Delivery <34 weeks 341 (5.18)
Delivery <37 weeks 1,092 (16.60)
doi:10.1371/journal.pone.0167716.t001
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Placental weight and birth weight were positively correlated (r = 0.54, P < 0.001). Placental
weight was positively associated with maternal age (r = 0.10, P < 0.001), gravidity (r = 0.10,
P< 0.001), and BMI at baseline (r = 0.14, P < 0.001).
Baseline characteristics of the women with samples processed for the protein analysis are
presented in S1 Table. The inter-assay coefficient of variability (CV) for all protein assays
(Ang1, Ang2, VEGF-A, PGF, and sFlt-1) was <11% and the intra-assay CV was <7%. Women
with Ang-2 (RR = 1.45 (1.10, 1.91), p = 0.047) in the highest quartile at enrolment had an
increased relative risk of placental weight in the bottom 10th percentile, while women with
VEGF-A (RR = 0.73 (0.56, 0.96), p = 0.013) and PGF (RR = 0.58 (0.44, 0.72), p = 0.002) in the
highest quartile had a reduced relative risk of placental weight at or below the 10th percentile
(Table 2). Risk of placental weight at or above the top 10th percentile was not associated with
levels of angiogenic proteins at enrolment (Table 2). Levels of Ang-1 and sFlt-1 were not asso-
ciated with extreme deciles of placental weight.
Placental weight below the 10th percentile was associated with an increased risk of adverse
perinatal outcomes (Fig 1). Low placental weight was associated with an increased relative risk
Table 2. Multivariate relative risk for placental weight according to biomarker levels by quartile
Placental Weight <10th Percentile
Q1 Q2 Q3 Q4 P-trend
Ang1 1.00 (Ref) 1.18 (0.87, 1.61) 1.42 (1.07, 1.89) 1.20 (0.89, 1.63) 0.1855
Ang2 1.00 (Ref) 1.19 (0.89, 1.59) 0.99 (0.74, 1.35) 1.45 (1.10, 1.91) 0.0132
VEGF-A 1.00 (Ref) 0.89 (0.66, 1.20) 0.84 (0.65, 1.09) 0.73 (0.56, 0.96) 0.0466
PGF 1.00 (Ref) 0.75 (0.57, 0.98) 0.67 (0.50, 0.89) 0.58 (0.44, 0.77) 0.0019
sFlt-1 1.00 (Ref) 1.04 (0.80, 1.36) 0.91 (0.69, 1.21) 0.80 (0.59, 1.07) 0.0637
Placental Weight >90th Percentile
Ang1 1.00 (Ref) 1.14 (0.66, 2.11) 1.36 (0.75, 2.47) 1.22 (0.66, 2.27) 0.5026
Ang2 1.00 (Ref) 0.96 (0.54, 1.72) 0.97 (0.54, 1.72) 0.88 (0.48, 1.62) 0.6837
VEGF-A 1.00 (Ref) 1.09 (0.56, 2.19) 1.07 (0.60, 1.90) 1.29 (0.76, 2.21) 0.3422
PGF 1.00 (Ref) 1.30 (0.66, 2.56) 0.18 (0.58, 2.41) 1.62 (0.85, 3.14) 0.1437
sFlt-1 1.00 (Ref) 0.82 (0.46, 1.45) 0.70 (0.38, 1.27) 0.70 (0.38, 1.28) 0.3322
Multivariate models adjusted for maternal age, literacy (yes/no), marital status (yes/no), baseline gestational age (weeks), and trial arm (multivitamin
supplementation/placebo). P-trend (p-value) for linear trend test calculated with median biomarker in each quartile as a continuous variable.
doi:10.1371/journal.pone.0167716.t002
Fig 1. Low placental weight is associated with an increased risk of adverse perinatal outcomes. Forest plots of adjusted relative risk for perinatal
outcomes with placental weight in (a) the bottom tenth percentile and (b) the top tenth percentile. Forest plots depict adjusted relative risk and 95% confidence
interval. Multivariate models adjusted for treatment arm (placebo, multivitamin), maternal age (years), sex of child (male, female), gestational age at trial
enrolment (weeks), and gestational age at delivery (week).
doi:10.1371/journal.pone.0167716.g001
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of Apgar score of<7 at 1 minute (RR = 2.31 (1.70, 3.13), p = 0.001), at 5 minutes (RR = 3.53
(2.34, 5.33), p = 0.001), neonatal death (RR = 5.02 (3.61, 7.00), p = 0.001), respiratory distress
(RR = 4.80(1.71, 13.45), p = 0.001), and seizures (RR = 4.18 (1.16, 15.02), p = 0.03) in multivar-
iate models including treatment arm, maternal age, sex of the child, gestational age at study
enrolment and gestational age at delivery (Table 3). High placental weight (> top 10th percen-
tile) was associated with an increased risk of an Apgar score<7 at 1 minute post-delivery
(RR = 1.54 (1.08, 2.18), p = 0.02), but was not associated with an increased risk of any other
adverse perinatal outcomes examined as part of this study (Table 3).
Discussion
We examined placental weight in association with angiogenic mediators and obstetric out-
comes in a cohort of women in Dar es Salaam, Tanzania. Low placental weight was associated
with altered levels of angiogenic factors at mid-pregnancy as well as an increased risk of
adverse perinatal outcomes. We observed that higher levels of Ang-2 at mid-gestation were
associated with a higher relative risk of placental weight in the bottom 10th percentile, while
higher levels of VEGF-A and PGF were associated with a lower relative risk of placental weight
in the bottom 10th percentile. Placental weight in the bottom 10th percentile was associated
with increased risk of an Apgar score <7, respiratory distress, seizure, and neonatal death.
Our findings suggest that higher levels of pro-angiogenic VEGF-A and PGF at mid-gesta-
tion (12–27 weeks) were associated with a higher placental weight. These findings are consis-
tent with abundant evidence in the literature indicating that VEGF-A and PGF mediate vessel
growth and remodelling at mid-gestation [1, 17, 21]. Early in gestation, VEGF-A regulates the
differentiation of mesenchymal cells into hemangioblastic cells in the villous core, as well as
subsequent proliferation, migration and sprouting [25, 26]. VEGF-A acts primarily on
VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1), which are expressed on the endothelium [27].
VEGFR-1 can be alternatively spliced generating the soluble Flt-1 receptor (sFlt-1), which
can bind circulating VEGF-A, removing it from circulation. Placental growth factor (PGF)
binds the Flt-1 receptor and appears to play a critical role in angiogenesis across gestation [18,
25, 26, 28]. Reduced circulating levels of PGF in pregnancy have been associated with placental
insufficiency, fetal growth restriction and subsequent late-onset small-for-gestational age out-
comes [29, 30]. The angiopoietins, Ang-1 and Ang-2, act in a context dependent manner with
Table 3. Relative risk of adverse perinatal outcomes dependent on placental weight in the bottom and top 10th percentiles
Placental Weight <10th Percentile Placental Weight >90th Percentile
Univariate Multivariate Univariate Multivariate
n/N RR (95% CI) P-value RR (95% CI) P-Value RR (95% CI) P-value RR (95% CI) P-Value
Apgar <7 at 1 min 308 2.44 (1.82, 3.27) 0.001 2.31 (1.70, 3.13) 0.001 1.48 (1.05, 2.10) 0.02 1.54 (1.08, 2.18) 0.02
Apgar <7 at 5 min 136 3.88 (2.63, 5.72) 0.001 3.53 (2.34, 5.33) 0.001 1.17 (0.65, 2.01) 0.60 1.17 (0.64, 2.17) 0.61
Neonatal Death 171 6.47 (4.77, 8.79) 0.001 5.02 (3.61, 7.00) 0.001 0.67 (0.33, 1.30) 0.24 0.81 (0.42, 1.58) 0.54
Asphyxia 56 1.60 (0.65, 3.98) 0.31 1.66 (0.66, 4.19) 0.28 0.93 (0.34, 2.57) 0.89 0.93 (0.33, 2.56) 0.88
Respiratory Distress 20 6.98 (2.70, 18.00) 0.001 4.80 (1.71, 13.45) 0.003 0.63 (0.09, 4.76) 0.66 0.81 (0.11, 6.05) 0.84
Seizures 16 3.76 (1.08, 13.14) 0.04 4.18 (1.16, 15.02) 0.03 2.80 (0.80, 9.77) 0.11 2.77 (0.78, 9.87) 0.12
Pneumonia 12 1.48 (0.19, 11.46) 0.70 1.83 (0.24, 14.38) 0.62 2.41 (0.53, 10.95) 0.32 2.31 (0.50, 10.6) 0.28
Sepsis 33 1.13 (0.27, 4.69) 0.87 0.42 (0.06, 3.07) 0.39 0.40 (0.05, 2.96) 0.37 0.43 (0.06, 3.20) 0.41
Relative risk (RR) and 95% confidence interval (CI) for perinatal outcomes with placental weight in the bottom and top 10th percentiles. Multivariate model
includes treatment arm (placebo, multivitamin), maternal age (years), sex of child (male, female), gestational age at trial enrolment (weeks) and gestational
age at delivery (weeks).
doi:10.1371/journal.pone.0167716.t003
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VEGF-A. Ang-1 and Ang-2 generally act as antagonists, competitively binding the Tie-2 recep-
tor. Binding of Ang-1 induces vascular maturation, whereas binding of Ang-2 causes destabili-
zation in the microvascular network and promotes angiogenesis [18, 28]. Since it is
problematic to quantify local levels of vasculogenic and angiogenic factors in the placenta, we
used maternal peripheral levels as a proxy to placental-derived proteins. Our results suggest
that higher circulating levels of pro-angiogenic VEGF-A and PGF at mid-pregnancy promote
placental growth and are therefore associated with a reduced risk of low placental weight. In
this cohort, high Ang-2 was associated with an increased relative risk of placental weight in the
bottom 10th percentile. Levels of Ang-2 typically decline across gestation [3]. Therefore ele-
vated Ang-2-associated lower placental weight may reflect a dysregulation in Ang-2 levels at
mid-pregnancy that precede the observed reduction in placental weight at delivery. For exam-
ple, compensatory mechanisms could lead to an increase in levels of pro-angiogenic Ang-2, in
pregnancies with low placental weight, in an attempt to increase vascularization in the pla-
centa. These results suggest that in this cohort the molecular events leading to disruptions in
placental development and ultimately changes in the placental weight may occur at earlier
time-points in pregnancy. Early alterations in angiogenic factors may be a risk factor for low
placental weight and adverse perinatal outcomes. Future studies examining angiogenic factors
at multiple time points across gestation and at delivery will be required to better characterize
changes in these proteins in association with placental weight and perinatal outcome.
We observed that low placental weight at delivery was associated with an increased risk of
adverse perinatal outcomes including low Apgar score, respiratory distress, seizures, and neona-
tal death. We also observed an increased risk of low Apgar score, at 1 minute but not at 5 min-
utes, associated with high placental weight (> top 10th percentile). We hypothesize that low
placental weight, as a result of low levels of pro-angiogenic factors at mid-pregnancy, leads to
inadequate nutrient support of the developing fetus and ultimately an increased risk of adverse
perinatal outcomes as a result of altered in utero development. In contrast to our observations, a
previous study conducted in Canada (Montreal, Quebec) reported an association between high
placental weight and low Apgar, respiratory distress, seizures and neonatal death [10]. The dis-
parity in our results may be a result of differences in the population demographics (maternal
age, BMI, gravidity) of pregnant women in low versus high resource settings. While we did
observe an association between high placental weight and low Apgar score at 1 minute, the
absence of this association at 5 minutes or an association with any other perinatal outcomes
examined in this study, doesn’t provide evidence of a strong association between high placental
weight and adverse perinatal outcomes in this cohort. Several authors have proposed that high
placental weight is a compensatory mechanism occurring in pregnancies with inadequate fetal
growth [10, 13, 31]. Poor nutrition and high infectious disease burden in resource-constrained
settings like Tanzania may mean that pregnant women in sub-Saharan Africa have other pro-
cesses contributing to placental vascular development, placental insufficiency and adverse birth
outcomes [23, 32]. Moreover they may lack sufficient nutritional intake to undergo the same
degree of compensatory mechanisms hypothesized to account for high placental weight.
Strengths of this study include its prospective design and access to a large cohort of women
with well-categorized demographic and clinical data that allows us to control for covariates
known to contribute to placental weight. Limitations include the nested and observational
nature of the study design. Although we set p< 0.05 as the cut off for significance in this
study, type I error rates may be inflated as a result of performing multiple tests. Further limita-
tions include the use of gestational dating by last menstrual period (LMP) at the time of enrol-
ment in the parent clinical trial. Access to gold-standard ultrasound technology for gestational
dating is limited in most resource-constrained settings necessitating the use of LMP. While we
recognize that this study would benefit from the use of first trimester ultrasound, this
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technology was unavailable at the time of the parent study. Future studies will need to prospec-
tively examine placental weight in relation to prevalent pregnancy complications such as, ges-
tational diabetes, malaria in pregnancy (confirmed by histology and PCR), gestational diabetes
and preeclampsia, which may impact placental weight. It is possible that this cohort had a
selection bias for mother-baby dyads with recorded placental weight. Home delivery is com-
mon in this region and may explain why 23% of deliveries in the parent trial had no recorded
placental weight. At home deliveries may be accompanied by higher rates of adverse outcomes,
which could be a consequence of changes in placental development and placental weight. Sev-
eral factors are capable of disrupting placental vasculogenesis and angiogenesis including
maternal nutritional status. In this cohort of women high rates of malnutrition could also
impact placental and fetal development. Multivitamin treatment in the parent trial was associ-
ated with a reduce risk of SGA and was included as a covariate in our analysis [23].
Previous research has associated maternal smoking, placental weight and changes in the
placental-fetal weight ratio [31, 33]. Due to extremely low rates of smoking in this cohort
(n = 32, 0.48%) we did not include smoking in the multivariate model and were unable to
assess the impact of smoking on placental weight. Malaria in pregnancy also contributes to
obstetric outcomes in endemic regions [34, 35]. Rates of malaria in pregnancy were also low in
this cohort (n = 130, 2.05% by RDT), which precluded an examination of the impact of malaria
on placental weight. Women enrolled in the parent trial lived in mostly urban areas and
received presumptive anti-malarial therapy at 20 and 30 weeks gestation, which may account
for the low rates of malaria in pregnancy at delivery. All women enrolled in the parent trial
received iron supplementation as part of their routine antenatal care. Iron supplementation in
combination with high rates of anemia at enrolment (53% of women in this cohort had base-
line haemoglobin levels below 10.5 g/dL) complicated an examination of an association
between maternal anemia and placental weight in this cohort.
The results of this study suggest that dysregulated levels of angiogenic factors at mid-preg-
nancy, including low circulating levels of pro-angiogenic VEGF and PGF, are associated with
low placental weight at delivery. Low placental weight was associated with an increased risk of
multiple adverse perinatal outcomes including neonatal death. We propose that placental
weight, as an easily assessed indicator in low resource settings, could have clinical utility in
risk-stratifying perinatal outcome. Moreover, evaluation of circulating angiogenic factors at
mid-pregnancy may provide insight into the growth of the placenta and therefore risk of
adverse outcomes after delivery. Easily assessed, low-cost parameters that enable early recogni-
tion of high-risk neonates could improve neonatal outcomes in resource-constrained settings.
Supporting Information
S1 Table. Baseline Characteristics of the Protein Analysis Study Cohort. Values depict
median [IQR] or number (%) where applicable.
(DOCX)
Acknowledgments
We would like to acknowledge and thank the mothers and children, field teams, including
nurses, midwives, supervisors, and laboratory staff, and administrative staff who made this
study possible.
Author Contributions
Conceptualization: CRM AMD KK WF.
Angiogenic proteins, placental weight and perinatal outcomes among pregnant women in Tanzania
PLOS ONE | DOI:10.1371/journal.pone.0167716 December 9, 2016 8 / 11
Data curation: CRM AMD WU SA.
Formal analysis: CRM AMD EL WF.
Funding acquisition: WU SA WF.
Investigation: CRM VT AC.
Methodology: CRM AMD WF.
Project administration: AMD WU SA WF.
Resources: WF KK.
Supervision: WF.
Visualization: CRM.
Writing – original draft: CRM AMD KK WF.
Writing – review & editing: CRM AMD KK WF.
References
1. Burton GJ, Charnock-Jones DS, Jauniaux E. Regulation of vascular growth and function in the human
placenta. Reproduction. 2009; 138(6):895–902. doi: 10.1530/REP-09-0092 PMID: 19470597
2. Karimu AL, Burton GJ. The distribution of microvilli over the villous surface of the normal human term
placenta is homogenous. Reprod Fertil Dev. 1995; 7(5):1269–73. PMID: 8848599
3. Geva E, Ginzinger DG, Zaloudek CJ, Moore DH, Byrne A, Jaffe RB. Human placental vascular develop-
ment: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vas-
cular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2. The Journal of clinical
endocrinology and metabolism. 2002; 87(9):4213–24. doi: 10.1210/jc.2002-020195 PMID: 12213874
4. Chisholm KM, Heerema-McKenney A, Tian L, Rajani AK, Saria S, Koller D, et al. Correlation of preterm
infant illness severity with placental histology. Placenta. 2016; 39:61–9. doi: 10.1016/j.placenta.2016.
01.012 PMID: 26992676
5. Ogunyemi D, Murillo M, Jackson U, Hunter N, Alperson B. The relationship between placental histopa-
thology findings and perinatal outcome in preterm infants. The journal of maternal-fetal & neonatal med-
icine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and
Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2003; 13(2):102–9.
6. Jones HN, Powell TL, Jansson T. Regulation of placental nutrient transport—a review. Placenta. 2007;
28(8–9):763–74. doi: 10.1016/j.placenta.2007.05.002 PMID: 17582493
7. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005; 308
(5728):1592–4. doi: 10.1126/science.1111726 PMID: 15947178
8. Thame M, Osmond C, Bennett F, Wilks R, Forrester T. Fetal growth is directly related to maternal
anthropometry and placental volume. Eur J Clin Nutr. 2004; 58(6):894–900. doi: 10.1038/sj.ejcn.
1601909 PMID: 15164110
9. Salafia CM, Charles AK, Maas EM. Placenta and fetal growth restriction. Clinical obstetrics and gyne-
cology. 2006; 49(2):236–56. PMID: 16721104
10. Hutcheon JA, McNamara H, Platt RW, Benjamin A, Kramer MS. Placental weight for gestational age
and adverse perinatal outcomes. Obstetrics and gynecology. 2012; 119(6):1251–8. doi: 10.1097/AOG.
0b013e318253d3df PMID: 22617591
11. Barker DJ, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS. Fetal nutrition and cardio-
vascular disease in adult life. Lancet. 1993; 341(8850):938–41. PMID: 8096277
12. Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM. Type 2 (non-insulin-dependent) diabe-
tes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabeto-
logia. 1993; 36(1):62–7. PMID: 8436255
13. Frankel S, Elwood P, Sweetnam P, Yarnell J, Smith GD. Birthweight, body-mass index in middle age,
and incident coronary heart disease. Lancet. 1996; 348(9040):1478–80. doi: 10.1016/S0140-6736(96)
03482-4 PMID: 8942776
Angiogenic proteins, placental weight and perinatal outcomes among pregnant women in Tanzania
PLOS ONE | DOI:10.1371/journal.pone.0167716 December 9, 2016 9 / 11
14. Risnes KR, Romundstad PR, Nilsen TI, Eskild A, Vatten LJ. Placental weight relative to birth weight and
long-term cardiovascular mortality: findings from a cohort of 31,307 men and women. American journal
of epidemiology. 2009; 170(5):622–31. doi: 10.1093/aje/kwp182 PMID: 19638481
15. Nyongo AD, Gichangi PB. Placental weights: do they have clinical significance? East Afr Med J. 1991;
68(3):239–40. PMID: 2070760
16. McNamara H, Hutcheon JA, Platt RW, Benjamin A, Kramer MS. Risk factors for high and low placental
weight. Paediatric and perinatal epidemiology. 2014; 28(2):97–105. doi: 10.1111/ppe.12104 PMID:
24354883
17. Mayhew TM, Charnock-Jones DS, Kaufmann P. Aspects of human fetoplacental vasculogenesis and
angiogenesis. III. Changes in complicated pregnancies. Placenta. 2004; 25(2–3):127–39. doi: 10.1016/
j.placenta.2003.10.010 PMID: 14972445
18. Charnock-Jones DS, Kaufmann P, Mayhew TM. Aspects of human fetoplacental vasculogenesis and
angiogenesis. I. Molecular regulation. Placenta. 2004; 25(2–3):103–13. doi: 10.1016/j.placenta.2003.
10.004 PMID: 14972443
19. Kaufmann P, Mayhew TM, Charnock-Jones DS. Aspects of human fetoplacental vasculogenesis and
angiogenesis. II. Changes during normal pregnancy. Placenta. 2004; 25(2–3):114–26. doi: 10.1016/j.
placenta.2003.10.009 PMID: 14972444
20. Kingdom J, Huppertz B, Seaward G, Kaufmann P. Development of the placental villous tree and its con-
sequences for fetal growth. European journal of obstetrics, gynecology, and reproductive biology. 2000;
92(1):35–43. PMID: 10986432
21. Wang Y, Zhao S. Vascular Biology of the Placenta. Integrated Systems Physiology: from Molecules to
Function to Disease. San Rafael (CA)2010.
22. Poston L, McCarthy AL, Ritter JM. Control of vascular resistance in the maternal and feto-placental arte-
rial beds. Pharmacology & therapeutics. 1995; 65(2):215–39.
23. Fawzi WW, Msamanga GI, Urassa W, Hertzmark E, Petraro P, Willett WC, et al. Vitamins and perinatal
outcomes among HIV-negative women in Tanzania. The New England journal of medicine. 2007; 356
(14):1423–31. doi: 10.1056/NEJMoa064868 PMID: 17409323
24. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Ameri-
can journal of epidemiology. 2005; 162(3):199–200. doi: 10.1093/aje/kwi188 PMID: 15987728
25. Leach L. The phenotype of the human materno-fetal endothelial barrier: molecular occupancy of para-
cellular junctions dictate permeability and angiogenic plasticity. J Anat. 2002; 200(6):599–606. PubMed
Central PMCID: PMC1570749. doi: 10.1046/j.1469-7580.2002.00062.x PMID: 12162727
26. Demir R, Kayisli UA, Seval Y, Celik-Ozenci C, Korgun ET, Demir-Weusten AY, et al. Sequential expres-
sion of VEGF and its receptors in human placental villi during very early pregnancy: differences between
placental vasculogenesis and angiogenesis. Placenta. 2004; 25(6):560–72. doi: 10.1016/j.placenta.
2003.11.011 PMID: 15135240
27. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously
encoded soluble receptor. Proceedings of the National Academy of Sciences of the United States of
America. 1993; 90(22):10705–9. PubMed Central PMCID: PMC47846. PMID: 8248162
28. Krauss T, Pauer HU, Augustin HG. Prospective analysis of placenta growth factor (PlGF) concentra-
tions in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia.
Hypertension in pregnancy: official journal of the International Society for the Study of Hypertension in
Pregnancy. 2004; 23(1):101–11.
29. Benton SJ, McCowan LM, Heazell AE, Grynspan D, Hutcheon JA, Senger C, et al. Placental growth
factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta. 2016; 42:1–8.
doi: 10.1016/j.placenta.2016.03.010 PMID: 27238707
30. Triunfo S, Lobmaier S, Parra-Saavedra M, Crovetto F, Peguero A, Nadal A, et al. Angiogenic factors at
diagnosis of late-onset small-for-gestational age and histological placental underperfusion. Placenta.
2014; 35(6):398–403. doi: 10.1016/j.placenta.2014.03.021 PMID: 24746262
31. Macdonald EM, Natale R, Regnault TR, Koval JJ, Campbell MK. Obstetric conditions and the placental
weight ratio. Placenta. 2014; 35(8):582–6. doi: 10.1016/j.placenta.2014.04.019 PMID: 24909371
32. Conroy AL, Silver KL, Zhong K, Rennie M, Ward P, Sarma JV, et al. Complement activation and the
resulting placental vascular insufficiency drives fetal growth restriction associated with placental
malaria. Cell Host Microbe. 2013; 13(2):215–26. doi: 10.1016/j.chom.2013.01.010 PMID: 23414761
33. Bush PG, Mayhew TM, Abramovich DR, Aggett PJ, Burke MD, Page KR. Maternal cigarette smoking
and oxygen diffusion across the placenta. Placenta. 2000; 21(8):824–33. doi: 10.1053/plac.2000.0571
PMID: 11095932
Angiogenic proteins, placental weight and perinatal outcomes among pregnant women in Tanzania
PLOS ONE | DOI:10.1371/journal.pone.0167716 December 9, 2016 10 / 11
34. Dellicour S, Tatem AJ, Guerra CA, Snow RW, ter Kuile FO. Quantifying the number of pregnancies at
risk of malaria in 2007: a demographic study. PLoS medicine. 2010; 7(1):e1000221. Epub 2010/02/04.
doi: 10.1371/journal.pmed.1000221 PMID: 20126256
35. Umbers AJ, Aitken EH, Rogerson SJ. Malaria in pregnancy: small babies, big problem. Trends in para-
sitology. 2011; 27(4):168–75. doi: 10.1016/j.pt.2011.01.007 PMID: 21377424
Angiogenic proteins, placental weight and perinatal outcomes among pregnant women in Tanzania
PLOS ONE | DOI:10.1371/journal.pone.0167716 December 9, 2016 11 / 11
